

Et oversettelsesvalg henger alltid tett sammen med vurderinger knyttet til det konkrete oversettelsesoppdraget (*translation brief*). Derfor følger her beskrivelsen av et tenkt oppdrag for oversettelse av nedenstående tekst, hentet fra nettstedet til London Stock Exchange: <https://alliancenews.com/in-depth-quantum-pharma-ceo-confident-despite-product-delays/> 11.03.2016.

*Translation brief*: Teksten skal brukes i en presentasjon av utvalgte børsnoterte utenlandske selskaper for en gruppe potensielle norske investorer.

#### IN DEPTH: QUANTUM PHARMA CEO CONFIDENT DESPITE PRODUCT DELAYS

[...]

LONDON (Alliance News) – Interim results from **Quantum Pharma PLC** were mixed Tuesday, as it proposed a maiden interim dividend and said it expects to meet market expectations for its full year, but it also warned that the launch of some of its products has been delayed and flagged slower-than-expected sales of vitamin D deficiency product Aviticol.

The niche pharmaceutical manufacturer said its pipeline of products continues to grow, standing at over 70 licensed pharmaceuticals and medical devices. However, a few products that were planned to launch earlier in the year have been delayed. It expects to have at least 10 products in the market by the end of the year.

Chief Executive Officer Andrew Scaife told Alliance News that of the ten, around half were delayed due to a number of reasons, including problems with scaling up manufacturing and with third parties. He said there wasn't "anything internally" that had caused the delays.

Scaife stressed that it was a case of "when, not if" those products would come through, and whilst there might be delays, they would never be anything that can't be overcome.

All of the 70 products are "achievable", Scaife said. Quantum would "potentially" face further delays in the future, he said, although these would not be the same issues, as they now know how to handle those. Plus, due to the large scope of the pipeline, "whilst we might get the odd delay here or there it clearly won't impact significantly," he said.

[...]

According to forecasts provided by Morningstar, N+1 Singer expects Quantum to report a pretax profit of GBP12.09 million for the full year to end-January, whilst Edison Research expects it to report a pretax profit of GBP12.7 million. The company reported a profit of GBP1.1 million in its 2015 financial year, after a loss of GBP2.6 million the year before.

Quantum proposed a maiden interim dividend per share of 0.5 pence. It had previously proposed a maiden final dividend of 0.25 pence with its full year results reported in May.

[...]